Liposomal Doxorubicin Market in Indonesia - Manufacturing and Consumption, Outlook and Forecast 2020-2026

April 2020 | 90 pages | ID: L258DED19D80EN
Market Monitor Global

Abstracts

Liposome doxorubicin is a commonly used anthracycline anti-tumor drug, and is one of the first-line drugs for ovarian cancer.

This report contains market size and forecasts of Liposomal Doxorubicin in Indonesia, including the following market information:
Indonesia Liposomal Doxorubicin Market Revenue, 2015-2020, 2021-2026, ($ millions)
Indonesia Liposomal Doxorubicin Market Consumption, 2015-2020, 2021-2026, (K Unit)
Indonesia Liposomal Doxorubicin Production Capacity, 2015-2020, 2021-2026, (K Unit)

Top Five Competitors in Indonesia Liposomal Doxorubicin Market 2019 (%)
The global Liposomal Doxorubicin market was valued at 1113.3 million in 2019 and is projected to reach US$ 1478 million by 2026, at a CAGR of 7.3% during the forecast period. While the Liposomal Doxorubicin market size in Indonesia was US$ XX million in 2019, and it is expected to reach US$ XX million by the end of 2026, with a CAGR of XX% during 2020-2026.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Liposomal Doxorubicin manufacturers, suppliers, distributors and industry experts on the impacts of the COVID-19 pandemic on businesses, with top challenges including ingredients and raw material delays, component and packaging shortages, reduced/cancelled orders from clients and consumers, and closures of production lines in some impacted areas.

This report also analyses and evaluates the COVID-19 impact on Liposomal Doxorubicin production and consumption in Indonesia

Total Market by Segment:

Indonesia Liposomal Doxorubicin Market, By Type, 2015-2020, 2021-2026 ($ millions) & (K Unit)
Indonesia Liposomal Doxorubicin Market Segment Percentages, By Type, 2019 (%)

• 5 ml
• 10 ml
• 25 ml
• The classification of liposomal doxorubicin includes 5ml, 10 ml, etc. And the proportion of 10ml in 2020 is estimated about 88.77%.

Indonesia Liposomal Doxorubicin Market, By Application, 2015-2020, 2021-2026 ($ millions) & (K Unit)
Indonesia Liposomal Doxorubicin Market Segment Percentages, By Application, 2019 (%)

• Breast Cancer
• Liver Cancer
• Kidney Cancer
• Multiple Myeloma
• Ovarian Cancer
• Other
• Liposomal doxorubicin is widely in breast cancer, liver cancer, kidney cancer, multiple myeloma, ovarian cancer, etc. the proportion of breast cancer in 2020 will be about 21.6%.

Competitor Analysis
The report also provides analysis of leading market participants including:
Total Liposomal Doxorubicin Market Competitors Revenues in Indonesia, by Players 2015-2020 (Estimated), ($ millions)
Total Liposomal Doxorubicin Market Competitors Revenues Share in Indonesia, by Players 2019 (%)
Total Indonesia Liposomal Doxorubicin Market Competitors Sales, by Players 2015-2020 (Estimated), (K Unit)
Total Indonesia Liposomal Doxorubicin Market Competitors Sales Market Share by Players 2019 ($ millions)
Further, the report presents profiles of competitors in the market, including the following:

• Johnson & Johnson
• Sun Pharmaceutical
• CSPC
• Kinyond
• Teva
• Fudan-Zhangjiang
• Zydus Cadila

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Liposomal Doxorubicin Market Definition
1.2 Market Segments
  1.2.1 Segment by Type
  1.2.2 Segment by Application
1.3 Indonesia Liposomal Doxorubicin Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 COVID-19 IMPACT: INDONESIA LIPOSOMAL DOXORUBICIN OVERALL MARKET SIZE

2.1 Indonesia Liposomal Doxorubicin Market Size: 2020 VS 2026
2.2 Indonesia Liposomal Doxorubicin Revenue, Prospects & Forecasts: 2015-2026
2.3 Indonesia Liposomal Doxorubicin Sales (Consumption): 2015-2026

3 COMPANY LANDSCAPE

3.1 Top Liposomal Doxorubicin Players in Indonesia (including Foreign and Local Companies)
3.2 Top Indonesia Liposomal Doxorubicin Companies Ranked by Revenue
3.3 Indonesia Liposomal Doxorubicin Revenue by Companies (including Foreign and Local Companies)
3.4 Indonesia Liposomal Doxorubicin Sales by Companies (including Foreign and Local Companies)
3.5 Indonesia Liposomal Doxorubicin Price by Manufacturer (2015-2020)
3.6 Top 3 and Top 5 Liposomal Doxorubicin Companies in Indonesia, by Revenue in 2019
3.7 Indonesia Manufacturers Liposomal Doxorubicin Product Type
3.8 Tier 1, Tier 2 and Tier 3 Liposomal Doxorubicin Players in Indonesia
  3.8.1 List of Indonesia Tier 1 Liposomal Doxorubicin Companies
  3.8.2 List of Indonesia Tier 2 and Tier 3 Liposomal Doxorubicin Companies

4 SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 By Type - Indonesia Liposomal Doxorubicin Market Size Markets, 2020 & 2026
  4.1.2 5 ml
  4.1.3 10 ml
  4.1.4 25 ml
4.2 By Type - Indonesia Liposomal Doxorubicin Revenue & Forecasts
  4.2.1 By Type - Indonesia Liposomal Doxorubicin Revenue, 2015-2020
  4.2.2 By Type - Indonesia Liposomal Doxorubicin Revenue, 2021-2026
  4.2.3 By Type - Indonesia Liposomal Doxorubicin Revenue Market Share, 2015-2026
4.3 By Type - Indonesia Liposomal Doxorubicin Sales & Forecasts
  4.3.1 By Type - Indonesia Liposomal Doxorubicin Sales, 2015-2020
  4.3.2 By Type - Indonesia Liposomal Doxorubicin Sales, 2021-2026
  4.3.3 By Type - Indonesia Liposomal Doxorubicin Sales Market Share, 2015-2026
4.4 By Type - Indonesia Liposomal Doxorubicin Price (Manufacturers Selling Prices), 2015-2026

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Indonesia Liposomal Doxorubicin Market Size, 2020 & 2026
  5.1.2 Breast Cancer
  5.1.3 Liver Cancer
  5.1.4 Kidney Cancer
  5.1.5 Multiple Myeloma
  5.1.6 Ovarian Cancer
  5.1.7 Other
5.2 By Application - Indonesia Liposomal Doxorubicin Revenue & Forecasts
  5.2.1 By Application - Indonesia Liposomal Doxorubicin Revenue, 2015-2020
  5.2.2 By Application - Indonesia Liposomal Doxorubicin Revenue, 2021-2026
  5.2.3 By Application - Indonesia Liposomal Doxorubicin Revenue Market Share, 2015-2026
5.3 By Application - Indonesia Liposomal Doxorubicin Sales & Forecasts
  5.3.1 By Application - Indonesia Liposomal Doxorubicin Sales, 2015-2020
  5.3.2 By Application - Indonesia Liposomal Doxorubicin Sales, 2021-2026
  5.3.3 By Application - Indonesia Liposomal Doxorubicin Sales Market Share, 2015-2026
5.4 By Application - Indonesia Liposomal Doxorubicin Price (Manufacturers Selling Prices), 2015-2026

6 MANUFACTURERS & BRANDS PROFILES

6.1 Johnson & Johnson
  6.1.1 Johnson & Johnson Corporate Summary
  6.1.2 Johnson & Johnson Business Overview
  6.1.3 Johnson & Johnson Liposomal Doxorubicin Major Product Offerings
  6.1.4 Johnson & Johnson Sales and Revenue in Indonesia (2015-2020)
  6.1.5 Johnson & Johnson Key News
6.2 Sun Pharmaceutical
  6.2.1 Sun Pharmaceutical Corporate Summary
  6.2.2 Sun Pharmaceutical Business Overview
  6.2.3 Sun Pharmaceutical Liposomal Doxorubicin Major Product Offerings
  6.2.4 Sun Pharmaceutical Sales and Revenue in Indonesia (2015-2020)
  6.2.5 Sun Pharmaceutical Key News
6.3 CSPC
  6.3.1 CSPC Corporate Summary
  6.3.2 CSPC Business Overview
  6.3.3 CSPC Liposomal Doxorubicin Major Product Offerings
  6.3.4 CSPC Sales and Revenue in Indonesia (2015-2020)
  6.3.5 CSPC Key News
6.4 Kinyond
  6.4.1 Kinyond Corporate Summary
  6.4.2 Kinyond Business Overview
  6.4.3 Kinyond Liposomal Doxorubicin Major Product Offerings
  6.4.4 Kinyond Sales and Revenue in Indonesia (2015-2020)
  6.4.5 Kinyond Key News
6.5 Teva
  6.5.1 Teva Corporate Summary
  6.5.2 Teva Business Overview
  6.5.3 Teva Liposomal Doxorubicin Major Product Offerings
  6.5.4 Teva Sales and Revenue in Indonesia (2015-2020)
  6.5.5 Teva Key News
6.6 Fudan-Zhangjiang
  6.6.1 Fudan-Zhangjiang Corporate Summary
  6.6.2 Fudan-Zhangjiang Business Overview
  6.6.3 Fudan-Zhangjiang Liposomal Doxorubicin Major Product Offerings
  6.6.4 Fudan-Zhangjiang Sales and Revenue in Indonesia (2015-2020)
  6.6.5 Fudan-Zhangjiang Key News
6.7 Zydus Cadila
  6.6.1 Zydus Cadila Corporate Summary
  6.6.2 Zydus Cadila Business Overview
  6.6.3 Zydus Cadila Liposomal Doxorubicin Major Product Offerings
  6.4.4 Zydus Cadila Sales and Revenue in Indonesia (2015-2020)
  6.7.5 Zydus Cadila Key News
6.8 TTY Biopharma
  6.8.1 TTY Biopharma Corporate Summary
  6.8.2 TTY Biopharma Business Overview
  6.8.3 TTY Biopharma Liposomal Doxorubicin Major Product Offerings
  6.8.4 TTY Biopharma Sales and Revenue in Indonesia (2015-2020)
  6.8.5 TTY Biopharma Key News

7 LIPOSOMAL DOXORUBICIN PRODUCTION CAPACITY, EXPORT AND IMPORT ANALYSIS

7.1 Liposomal Doxorubicin Production Capacity and Value in Indonesia, Situation Analysis and Prediction, 2015-2026
  7.1.1 Indonesia Liposomal Doxorubicin Production Capacity, 2015-2026
  7.1.2 Indonesia Liposomal Doxorubicin Production 2015-2026
  7.1.3 Indonesia Liposomal Doxorubicin Production Value 2015-2026
7.2 Key Local Liposomal Doxorubicin Manufacturers in Indonesia
  7.2.1 Indonesia Key Local Liposomal Doxorubicin Manufacturers Production Capacity
  7.2.2 Indonesia Key Local Liposomal Doxorubicin Manufacturers Production
  7.2.3 Indonesia Key Local Liposomal Doxorubicin Manufacturers Production Value
  7.2.4 The Proportion of Liposomal Doxorubicin Production Sold in Indonesia and Sold Other Than Indonesia by Manufacturers
7.3 Liposomal Doxorubicin Export and Import in Indonesia
  7.3.1 Indonesia Liposomal Doxorubicin Export Market
  7.3.2 Indonesia Liposomal Doxorubicin Source of Imports

8 COVID-19 IMPACT: KEY MARKET TRENDS, OPPORTUNITY, DRIVERS AND RESTRAINTS

8.1 PESTLE Analysis for Indonesia Liposomal Doxorubicin Market
8.2 Market Opportunities & Trends
8.3 Market Drivers
8.4 Market Restraints

9 COVID-19 IMPACT ON LIPOSOMAL DOXORUBICIN SUPPLY CHAIN ANALYSIS

9.1 Supply Chain Analysis
9.2 Upstream Market Analysis
9.3 Downstream and Clients Market Analysis
9.4 Marketing Channels Analysis
  9.4.1 Marketing Channels
  9.4.2 Liposomal Doxorubicin Distributors and Sales Agents in Indonesia

10 CONCLUSION

11 APPENDIX

11.1 Note
11.2 Examples of Clients
11.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Key Players of Liposomal Doxorubicin in Indonesia
Table 2. Top Players in Indonesia, Ranking by Revenue (2019)
Table 3. Indonesia Liposomal Doxorubicin Revenue by Companies, (US$, Mn), 2015-2020
Table 4. Indonesia Liposomal Doxorubicin Revenue Share by Companies, 2015-2020
Table 5. Indonesia Liposomal Doxorubicin Sales by Companies, (K Unit), 2015-2020
Table 6. Indonesia Liposomal Doxorubicin Sales Share by Companies, 2015-2020
Table 7. Key Manufacturers Liposomal Doxorubicin Price (2015-2020) (USD/Unit)
Table 8. Indonesia Manufacturers Liposomal Doxorubicin Product Type
Table 9. List of Indonesia Tier 1 Liposomal Doxorubicin Companies, Revenue (US$, Mn) in 2019 and Market Share
Table 10. List of Indonesia Tier 2 and Tier 3 Liposomal Doxorubicin Companies, Revenue (US$, Mn) in 2019 and Market Share
Table 11. By Type - Liposomal Doxorubicin Revenue in Indonesia (US$, Mn), 2015-2020
Table 12. By Type - Liposomal Doxorubicin Revenue in Indonesia (US$, Mn), 2021-2026
Table 13. By Type - Liposomal Doxorubicin Sales in Indonesia (K Unit), 2015-2020
Table 14. By Type - Liposomal Doxorubicin Sales in Indonesia (K Unit), 2021-2026
Table 15. By Application - Liposomal Doxorubicin Revenue in Indonesia, (US$, Mn), 2015-2020
Table 16. By Application - Liposomal Doxorubicin Revenue in Indonesia, (US$, Mn), 2021-2026
Table 17. By Application - Liposomal Doxorubicin Sales in Indonesia, (K Unit), 2015-2020
Table 18. By Application - Liposomal Doxorubicin Sales in Indonesia, (K Unit), 2021-2026
Table 19. Johnson & Johnson Corporate Summary
Table 20. Johnson & Johnson Liposomal Doxorubicin Product Offerings
Table 21. Johnson & Johnson Liposomal Doxorubicin Sales (K Unit), Revenue (US$, Mn) and Average Price (USD/Unit) (2015-2020)
Table 22. Sun Pharmaceutical Corporate Summary
Table 23. Sun Pharmaceutical Liposomal Doxorubicin Product Offerings
Table 24. Sun Pharmaceutical Liposomal Doxorubicin Sales (K Unit), Revenue (US$, Mn) and Average Price (USD/Unit) (2015-2020)
Table 25. CSPC Corporate Summary
Table 26. CSPC Liposomal Doxorubicin Product Offerings
Table 27. CSPC Liposomal Doxorubicin Sales (K Unit), Revenue (US$, Mn) and Average Price (USD/Unit) (2015-2020)
Table 28. Kinyond Corporate Summary
Table 29. Kinyond Liposomal Doxorubicin Product Offerings
Table 30. Kinyond Liposomal Doxorubicin Sales (K Unit), Revenue (US$, Mn) and Average Price (USD/Unit) (2015-2020)
Table 31. Teva Corporate Summary
Table 32. Teva Liposomal Doxorubicin Product Offerings
Table 33. Teva Liposomal Doxorubicin Sales (K Unit), Revenue (US$, Mn) and Average Price (USD/Unit) (2015-2020)
Table 34. Fudan-Zhangjiang Corporate Summary
Table 35. Fudan-Zhangjiang Liposomal Doxorubicin Product Offerings
Table 36. Fudan-Zhangjiang Liposomal Doxorubicin Sales (K Unit), Revenue (US$, Mn) and Average Price (USD/Unit) (2015-2020)
Table 37. Zydus Cadila Corporate Summary
Table 38. Zydus Cadila Liposomal Doxorubicin Product Offerings
Table 39. Zydus Cadila Liposomal Doxorubicin Sales (K Unit), Revenue (US$, Mn) and Average Price (USD/Unit) (2015-2020)
Table 40. TTY Biopharma Corporate Summary
Table 41. TTY Biopharma Liposomal Doxorubicin Product Offerings
Table 42. TTY Biopharma Liposomal Doxorubicin Sales (K Unit), Revenue (US$, Mn) and Average Price (USD/Unit) (2015-2020)
Table 43. Liposomal Doxorubicin Production Capacity (K Unit) of Local Manufacturers in Indonesia, 2015-2020
Table 44. Liposomal Doxorubicin Production (K Unit) of Local Manufacturers in Indonesia, 2015-2020
Table 45. Indonesia Liposomal Doxorubicin Production Market Share of Local Manufacturers, 2015-2020
Table 46. Liposomal Doxorubicin Production Value (US$, Mn) of Local Manufacturers in Indonesia, 2015-2020
Table 47. Indonesia Liposomal Doxorubicin Production Value Market Share of Local Manufacturers, 2015-2020
Table 48. The Percentage of Liposomal Doxorubicin Production Sold in Indonesia and Sold Other Than Indonesia by Manufacturers
Table 49. The Percentage of Liposomal Doxorubicin Production Sold in Indonesia and Sold Other Than Indonesia by Manufacturers
Table 50. Dangeguojia Liposomal Doxorubicin Sales (Consumption), Production, Export and Import, 2015-2020
Table 51. Raw Materials and Suppliers
Table 52. Liposomal Doxorubicin Downstream Clients in Indonesia
Table 53. Liposomal Doxorubicin Distributors and Sales Agents in Indonesia

List Of Figures

LIST OF FIGURES

Figure 1. Liposomal Doxorubicin Segment by Type
Figure 2. Liposomal Doxorubicin Segment by Application
Figure 3. Dangeguojia Liposomal Doxorubicin Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Liposomal Doxorubicin Market Size in Indonesia, (US$, Mn) & (K Unit): 2020 VS 2026
Figure 6. Indonesia Liposomal Doxorubicin Revenue, 2015-2026 (US$, Mn)
Figure 7. Liposomal Doxorubicin Sales in Indonesia: 2015-2026 (K Unit)
Figure 8. The Top 3 and 5 Players Market Share by Liposomal Doxorubicin Revenue in 2019
Figure 9. By Type - Indonesia Liposomal Doxorubicin Incremental Growth, (US$, Mn), 2015-2026
Figure 10. By Type - Indonesia Liposomal Doxorubicin Market Share, 2015-2020
Figure 11. By Type - Indonesia Liposomal Doxorubicin Market Share, 2020-2026
Figure 12. By Type - Indonesia Liposomal Doxorubicin Price (USD/Unit), 2015-2026
Figure 13. By Application - Liposomal Doxorubicin Revenue in Indonesia (US$, Mn), 2020 & 2026
Figure 14. By Application - Indonesia Liposomal Doxorubicin Market Share, 2015-2020
Figure 15. By Application - Indonesia Liposomal Doxorubicin Market Share, 2020-2026
Figure 16. By Application -Indonesia Liposomal Doxorubicin Price (USD/Unit), 2015-2026
Figure 17. Indonesia Liposomal Doxorubicin Production Capacity (K Unit), 2015-2026
Figure 18. Indonesia Liposomal Doxorubicin Actual Output (K Unit), 2015-2026
Figure 19. Indonesia Liposomal Doxorubicin Production Value (US$, Mn), 2015-2026
Figure 20. The Percentage of Indonesia Liposomal Doxorubicin Export Destination, 2019
Figure 21. The Source of Imports of Indonesia Liposomal Doxorubicin, 2019
Figure 22. PEST Analysis for Indonesia Liposomal Doxorubicin Market in 2020
Figure 23. Liposomal Doxorubicin Market Opportunities & Trends in Indonesia
Figure 24. Liposomal Doxorubicin Market Drivers in Indonesia
Figure 25. Liposomal Doxorubicin Market Restraints in Indonesia
Figure 26. Liposomal Doxorubicin Industry Value Chain